MX2016015791A - Composiciones de omega-3, formas de dosis, y metodos de uso. - Google Patents

Composiciones de omega-3, formas de dosis, y metodos de uso.

Info

Publication number
MX2016015791A
MX2016015791A MX2016015791A MX2016015791A MX2016015791A MX 2016015791 A MX2016015791 A MX 2016015791A MX 2016015791 A MX2016015791 A MX 2016015791A MX 2016015791 A MX2016015791 A MX 2016015791A MX 2016015791 A MX2016015791 A MX 2016015791A
Authority
MX
Mexico
Prior art keywords
compositions
dosage forms
omega
methods
disclosed
Prior art date
Application number
MX2016015791A
Other languages
English (en)
Spanish (es)
Inventor
Sandnes Olav
A Miller Bruce
Dyerberg Jorn
Stender Steen
Original Assignee
Marine Ingredients Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Ingredients Llc filed Critical Marine Ingredients Llc
Publication of MX2016015791A publication Critical patent/MX2016015791A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2016015791A 2014-06-06 2015-06-05 Composiciones de omega-3, formas de dosis, y metodos de uso. MX2016015791A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462009145P 2014-06-06 2014-06-06
US201462019289P 2014-06-30 2014-06-30
PCT/US2015/034372 WO2015188046A1 (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use

Publications (1)

Publication Number Publication Date
MX2016015791A true MX2016015791A (es) 2017-05-30

Family

ID=54767418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015791A MX2016015791A (es) 2014-06-06 2015-06-05 Composiciones de omega-3, formas de dosis, y metodos de uso.

Country Status (14)

Country Link
US (4) US9675575B2 (enExample)
EP (2) EP3906920A1 (enExample)
JP (2) JP6755186B2 (enExample)
KR (1) KR102400958B1 (enExample)
CN (1) CN106687113B (enExample)
AU (1) AU2015269307C1 (enExample)
BR (1) BR112016028561A8 (enExample)
CA (1) CA2950344C (enExample)
CL (1) CL2016003131A1 (enExample)
MX (1) MX2016015791A (enExample)
MY (1) MY186566A (enExample)
RU (1) RU2741965C2 (enExample)
TW (1) TWI725937B (enExample)
WO (1) WO2015188046A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
EP3906920A1 (en) * 2014-06-06 2021-11-10 Marine Ingredients, LLC Omega-3 compositions, dosage forms, and methods of use
CN110958731A (zh) 2018-09-21 2020-04-03 鸿盛国际有限公司 发光二极管并联电路
FR3103355B1 (fr) 2019-11-26 2024-05-31 Polaris Composition d’huile de micro-organismes enrichie en acides gras polyinsaturés
FR3151183A1 (fr) 2023-07-20 2025-01-24 Microphyt Nouvelle utilisation d’un extrait de la microalgue Phaeodactylum tricornutum

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2731015B1 (fr) 1995-02-24 1997-05-30 Sci Sartone Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus
AU729424B2 (en) * 1995-11-24 2001-02-01 Unilever Plc Composition based on fish oil
US7799365B2 (en) * 2001-04-06 2010-09-21 Burnbrae Farms Limited Liquid egg composition including fish oil with omega-3 fatty acid
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
SE0303513D0 (sv) * 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US20070020340A1 (en) * 2005-07-25 2007-01-25 David Rubin Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
WO2007066232A2 (en) 2005-10-07 2007-06-14 Ocean Nutrition Canada Ltd. Salts of fatty acids and methods of making and using thereof
MX286464B (es) 2005-12-20 2011-05-10 Cenestra Llc Formulaciones de acido graso omega 3.
KR101256448B1 (ko) 2005-12-21 2013-04-19 브루디 테크놀로지 에스엘 세포의 산화적 손상과 연관된 병리상태를 치료하기 위한ｄｈａ, ｅｐａ 또는 ｄｈａ 유래의 ｅｐａ의 용도
CA2656028A1 (en) 2006-06-23 2007-12-27 The Procter & Gamble Company Concentrated omega-3 fatty acids and mixtures containing them
WO2008036353A2 (en) 2006-09-19 2008-03-27 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
CA2685272A1 (en) * 2007-04-26 2008-11-06 Patrick Adlercreutz A polyunsaturated fatty acid (pufa) enriched marine oil comprising eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and a process of production thereof
US20100119600A1 (en) 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
CL2008002020A1 (es) 2007-07-12 2008-11-14 Ocean Nutrition Canada Ltd Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite.
CN101765662B (zh) * 2007-07-30 2014-04-02 日本水产株式会社 Epa浓缩油和dha浓缩油的制造方法
KR101045397B1 (ko) 2008-07-04 2011-06-30 주식회사동우산업 오메가-3 지방산 함량이 높은 정제 오징어유의 제조방법
GB0813599D0 (en) 2008-07-24 2008-09-03 Pharma Marine As Method
RS53694B1 (sr) * 2008-08-07 2015-04-30 Spa Societa' Prodotti Antibiotici S.P.A. Dugoročno lečenje simptomatske srčane insuficijencije
US20100236137A1 (en) * 2008-09-23 2010-09-23 LiveFuels, Inc. Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae
BRPI1009431A2 (pt) * 2009-03-09 2016-03-01 Pronova Biopharma Norge As pré-concentrados farmacêuticos e de suplemento alimentar, sistemas de liberação de droga, método de tratamento de pelo menos um problema de saúde em sujeito em necessidade do mesmo e método e sistema
CN101695487B (zh) * 2009-09-22 2012-01-18 北京百慧生化制药有限责任公司 一种高纯度epa-e、dha-e的多烯酸乙酯乳剂
FR2955459B1 (fr) 2010-01-28 2013-11-22 Polaris Composition huileuse riche en monoglycerides de dha
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
WO2011133841A2 (en) 2010-04-23 2011-10-27 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Intravenous omega-3 fatty acid compositions & method of use
SG188626A1 (en) * 2010-09-24 2013-04-30 Pronova Biopharma Norge As Process for concentrating omega-3 fatty acids
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
WO2013086323A2 (en) * 2011-12-08 2013-06-13 Metaproteomics, Llc Supplemented oil compositions and methods for improved health
EP2793867B1 (en) * 2011-12-22 2021-01-20 Baes, Erik Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
CA2873055C (en) 2012-05-10 2023-10-10 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
EP3756658A1 (en) 2012-09-24 2020-12-30 Aker Biomarine Antarctic As Omega -3 compositions
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
EP3906920A1 (en) 2014-06-06 2021-11-10 Marine Ingredients, LLC Omega-3 compositions, dosage forms, and methods of use

Also Published As

Publication number Publication date
MY186566A (en) 2021-07-27
TWI725937B (zh) 2021-05-01
US9675575B2 (en) 2017-06-13
BR112016028561A2 (pt) 2017-08-22
KR20170018825A (ko) 2017-02-20
KR102400958B1 (ko) 2022-05-20
AU2015269307B2 (en) 2019-03-14
RU2016149416A3 (enExample) 2018-12-05
EP3151826A4 (en) 2018-01-24
CA2950344C (en) 2023-09-19
RU2741965C2 (ru) 2021-02-01
US10034849B2 (en) 2018-07-31
EP3151826A1 (en) 2017-04-12
EP3906920A1 (en) 2021-11-10
AU2015269307C1 (en) 2019-10-03
TW201613571A (en) 2016-04-16
US20170252313A1 (en) 2017-09-07
US20180303784A1 (en) 2018-10-25
CN106687113A (zh) 2017-05-17
US10172819B2 (en) 2019-01-08
CN106687113B (zh) 2021-09-03
RU2016149416A (ru) 2018-07-10
WO2015188046A1 (en) 2015-12-10
CA2950344A1 (en) 2015-12-10
JP6755186B2 (ja) 2020-09-16
CL2016003131A1 (es) 2017-06-09
BR112016028561A8 (pt) 2021-06-29
JP2017516811A (ja) 2017-06-22
AU2015269307A1 (en) 2017-01-05
US20160243068A1 (en) 2016-08-25
JP2020105224A (ja) 2020-07-09
US20210308086A1 (en) 2021-10-07
US11160777B2 (en) 2021-11-02

Similar Documents

Publication Publication Date Title
IL268406A (en) Preparations and methods for treating hemoglobin diseases
IL260257A (en) Preparations and methods for the treatment of hemoglobinopathies
EP4620520A3 (en) Methods and compositions relating to chondrisomes
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
IL290150A (en) Compounds and methods for treating chronic pain
GB2541571A (en) Pharmaceutical compositions
EP3134130A4 (en) Compositions and methods to treating hemoglobinopathies
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
IL262348A (en) Preparations for the treatment of excessive radiation disorders
MX2017002489A (es) Agentes terapeuticos humanos.
MY190647A (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
IL246856A0 (en) A combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
TW201613571A (en) OMWGA-3 compositions, dosage forms, and methods of use
LT3229790T (lt) Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme
ZA201807858B (en) Plant treatment composition
SG11201700123UA (en) Coix seed oil comprising 11 triglycerides, formulation and application thereof
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
EP3169684A4 (en) Methods and compositions for treating hiv-related disorders
GEP20196977B (en) Pharmaceutical formulations of vildagliptin
PH12016502311A1 (en) Omega-3 analogues
EP3673073A4 (en) PRODUCTION OF EPA- AND DHA-ENRICHED GLYCERIDES
WO2015191760A3 (en) Compositions and methods for treating rheumatoid arthritis
WO2015123480A3 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
HK40015941A (en) Compositions and methods for the treatment of hemoglobinopathies